2 Information about atezolizumab

Marketing authorisation indication

2.1 Atezolizumab (Tecentriq, Roche) 'in combination with nab‑paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD‑L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price for atezolizumab is £2,665.38 per 840 mg/14 ml vial (excluding VAT, BNF online accessed April 2020). The company has a commercial arrangement, which makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)